Jan Lundberg Joins TB Alliance Board of Directors
NEW YORK, Jan. 15, 2019 /PRNewswire/ -- TB Alliance, a not-for-profit organization dedicated to developing new drug regimens to fight tuberculosis (TB), has appointed Dr. Jan Lundberg to its Board of Directors. Dr. Lundberg brings 22 years of experience in the pharmaceutical industry and 15 years as a top executive, including more than eight years as President of Lilly Research Laboratories and Executive Vice President of Science and Technology at Eli Lilly and Company.
"I have been a part of the research, discovery and development of new treatments in a variety of therapeutic areas, and it is clear that the development of new, innovative treatments for tuberculosis is urgently needed," said Dr. Lundberg. "I am thrilled to be serving on the TB Alliance Board as the organization works to address this unmet need and improve the lives of millions of people impacted by this disease around the world."
Dr. Lundberg was responsible for global research and development (R&D) management during his tenure at Eli Lilly, which included the approval of 12 products over his nearly eight-and-a-half-year tenure. In his previous role at AstraZeneca he was global head of discovery research, including for infectious diseases and a TB Research facility in Bangalore, India.
"We are very excited to have Dr. Lundberg join as a member of the Board," said Dr. Mel Spigelman, President and CEO of TB Alliance. "As we continue to advance the discovery and development of transformative TB drug regimens, his expertise and experience will be a tremendous benefit to TB Alliance and our goal of ending TB."
In addition to his experience at Eli Lilly, Dr. Lundberg is the cofounder of Aerocrine AB and currently serves on the boards of Ardelyx, Betagenon and Image Analysis Group. He was a professor in the Department of Pharmacology at Karolinska Institute in Stockholm and has been a member of several governmental committees in both the European Union and the United States. Dr. Lundberg received his medical education from the University of Gothenburg and a Ph.D. from the Karolinska Institute.
About TB Alliance
TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis (TB). Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australia's Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, Germany's Federal Ministry of Education and Research through KfW, Global Health Innovative Technology Fund, Indonesia Health Fund, Innovative Medicines Initiative, Irish Aid, Medical Research Council, National Institute of Allergy and Infectious Disease, Netherlands Ministry of Foreign Affairs, United Kingdom Department for International Development, UK Department of Health, United States Agency for International Development, and the United States Food and Drug Administration.
For more information contact:
Thomas Lynch +1 (646) 616-8639 / email@example.com